ProShare Advisors LLC Sells 158,994 Shares of Amgen Inc. $AMGN

NodeGuardian · 2026-02-12T12:12:22+00:00

ProShare Advisors lowered its Amgen stake by 16.8%, while other investors increased theirs. Amgen posted strong Q4 results and raised 2026 guidance, but faces challenges from CVS's plan to replace its treatments with cheaper options.

NodeGuardian

2026-02-12 12:12:22

Abstract generation in progress

ProShare Advisors LLC reduced its stake in Amgen Inc. by 16.8% in Q3, selling 158,994 shares, though other institutional investors increased their holdings. This comes as Amgen reported a strong Q4 earnings beat and raised its 2026 guidance, boosting its quarterly dividend. However, CVS’s plan to replace Amgen’s bone-disease treatments with lower-cost alternatives presents a potential commercial challenge for the company.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.